Robert I. Haddad
Brigham and Women's Hospital(US)Centre National de la Recherche Scientifique(FR)Sharif University of Technology(IR)Harvard University(US)Université Clermont Auvergne(FR)Laboratoire de Physique de Clermont Auvergne(FR)California Institute of Behavioral Neurosciences and Psychology (United States)(US)Dana-Farber Cancer Institute(US)Institut National de Physique Nucléaire et de Physique des Particules(FR)Hôpital Antoine-Béclère(FR)Dana-Farber Brigham Cancer Center(US)
Publications by Year
Research Areas
Head and Neck Cancer Studies, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Cancer Diagnosis and Treatment
Most-Cited Works
- → Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck(2016)4,966 cited
- → Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer(2007)1,696 cited
- → Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology(2020)1,337 cited
- → Recent Advances in Head and Neck Cancer(2008)924 cited
- → Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort(2016)850 cited
- → Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression(2018)786 cited